查看购物车
  • Traditional Chinese
  • English
  • Japanese
  • Korean
封面
市场调查报告书
商品编码
1930136

全球坐骨神经痛治疗市场：市场规模、占有率、成长率、产业分析、依类型、应用和地区划分的分析以及未来预测（2026-2034）

Sciatica Treatment Market Size, Share, Growth and Global Industry Analysis By Type & Application, Regional Insights and Forecast to 2026-2034
出版日期: | 出版商: Fortune Business Insights Pvt. Ltd. | 英文 110 Pages | 商品交期: 请询问到货日

价格

坐骨神经痛治疗市场成长因素

预计2025年全球坐骨神经痛治疗市场规模将达59.2亿美元，从2026年的65.2亿美元成长至2034年的144.2亿美元，预测期内复合年增长率高达10.44%。北美将在2025年以46.1%的市场占有率引领市场，这主要得益于人们对慢性腰痛的高度关注、处方量的增长以及大型製药公司的存在。

坐骨神经痛（也称为腰椎神经根性疼痛）的特征是由于坐骨神经受压或受刺激而引起的疼痛从腰部放射至腿部。椎间盘突出、椎管狭窄和腰椎神经根病变的发生率不断上升，推动了全球对有效药物和介入治疗的需求。

市场驱动因素

市场成长的主要驱动因素是全球坐骨神经痛盛行率的上升。年盛行率介于1.0%至5.0%之间，终生盛行率介于13%至40%之间。非处方药和处方药（包括非类固醇抗发炎药 (NSAIDs)、皮质类固醇、抗忧郁药和鸦片类药物）的日益普及，显着推动了治疗方案的采用。

人们对硬膜外类固醇注射和疼痛管理疗法等先进疗法的认识不断提高，以及市场参与者临床试验活动的增加，进一步推动了市场扩张。此外，缺乏获得 FDA 批准的长期治疗方案也促使企业投资于创新药物研发计画。

新冠疫情的影响

2020 年，由于就诊量减少以及药品生产和供应链中断，新冠疫情对坐骨神经痛治疗市场产生了负面影响。由于医疗系统优先治疗新冠患者，处方量下降。

然而，随着疫情后的復苏，慢性病患者的就诊量已恢復。到 2021 年，随着限制措施的放鬆，对坐骨神经痛治疗的需求增加，製药公司在医院和零售药局的处方药销售额也随之增长。

市场趋势

影响市场发展的关键趋势之一是医疗机构和研究机构所进行的宣传教育活动日益增加。大众对坐骨神经痛的症状、风险因素和治疗方案的了解不断加深，从而提高了早期诊断和治疗率。

国家和地区层级针对慢性下背痛管理和推广非鸦片类镇痛疗法的措施正在影响处方模式。微创手术和非鸦片类药物在医疗机构的普及进一步推动了市场成长。

限制因子

儘管市场成长前景强劲，但长期治疗坐骨神经痛的副作用和併发症正在限制市场发展。长期使用皮质类固醇、鸦片类药物和侵入性治疗可能导致严重的併发症，从而限制了这些疗法的普及。

此外，坐骨神经痛的治疗会带来沉重的经济负担，因为其直接和间接的医疗成本都很高。现有疗法的长期疗效有限，以及对感染和全身性副作用等併发症的担忧，可能会限制市场成长。

市场区隔分析

依类型划分：

预计到2026年，慢性坐骨神经痛市场将占主导地位，市场占有率高达71.47%，这主要得益于持续性疼痛的高发生率以及硬膜外注射和阿片类药物疗法的日益普及。急性坐骨神经痛市场预计将稳定成长，这得益于人们对该疾病的认识不断提高以及早期治疗的推广。

依药物类别划分：

到2026年，非类固醇抗发炎药物 (NSAID) 市场占有率将达到44.17%，这主要得益于其广泛的可及性、价格优势以及处方频率。由于硬膜外类固醇注射的需求不断增长，预计皮质类固醇的增长速度最快。

依分销管道划分：

到2026年，零售和线上药局通路将占市场主导地位，市占率达到80.52%，这主要得益于较高的自付费用以及疼痛管理药物的便捷取得。由于住院患者数量的增加，预计医院药房也将保持稳定成长。

区域因素

  • 北美：预计到2025年，北美市场规模将达到27.3亿美元，主要得益于较高的处方率和较高的药物认知度。 预计到2026年，美国市场规模将达到29.3亿美元。 欧洲：由于疾病高发生率和系统化的疼痛管理指南，市场预计将保持温和成长。 亚太地区：由于背痛发病率上升和政府举措，预计市场将具有强劲的成长潜力。预计到2026年，日本市场规模将达到2.8亿美元，中国将达到2.4亿美元，印度将达到1.7亿美元。 拉丁美洲、中东和非洲：由于疼痛管理疗法的普及，预计市场将保持稳定成长。

目录

第一章：引言

第二章：摘要整理

第三章：市场动态

  • 市场驱动因素
  • 市场限制因素
  • 市场机遇
  • 市场趋势

第四章：关键考虑因素

  • 主要国家/地区坐骨神经痛盛行率（2025 年）
  • 主要公司近期产品发布
  • 关键产业趋势：併购、业务合作
  • 新冠疫情对全球市场的影响

第五章 全球坐骨神经痛治疗市场分析：洞察与预测（2021-2034）

  • 市场分析、洞察与预测：依类型划分
    • 急性
    • 慢性
  • 市场分析、洞察与预测：依药物类别划分
    • 非类固醇抗发炎药 (NSAIDs)
    • 皮质类固醇
    • 抗忧郁药
    • 其他
  • 市场分析、洞察与预测：依通路划分
    • 医院药房
    • 零售和线上药房
  • 市场分析、洞察与预测：依地区划分
    • 北美
    • 欧洲
    • 亚太地区
    • 拉丁美洲
    • 中东和非洲

第六章 北美坐骨神经痛治疗市场分析：洞察与预测（2021-2034）

  • 依国家划分
    • 美国
    • 加拿大

第七章：欧洲坐骨神经痛治疗市场分析：洞察与预测（2021-2034）

  • 依国家划分
    • 英国
    • 德国
    • 法国
    • 西班牙
    • 义大利
    • 其他欧洲国家

第八章：亚太地区坐骨神经痛治疗市场分析：洞察与预测（2021-2034）

  • 依国家划分
    • 日本
    • 中国
    • 印度
    • 澳大利亚
    • 东南亚亚洲
    • 亚太其他地区

第九章：拉丁美洲坐骨神经痛治疗市场分析：洞察与预测（2021-2034）

  • 依国家划分
    • 巴西
    • 墨西哥
    • 拉丁美洲其他地区

第十章：中东与非洲坐骨神经痛治疗市场分析：洞察与预测（2021-2034）

  • 依国家划分
    • 海湾合作委员会（GCC）国家
    • 南非
    • 中东和非洲其他地区

第11章 竞争分析

  • 世界市场占有率分析(2025年)
  • 企业简介
    • Pfizer Inc.
    • Abbott
    • Bayer AG
    • Endo International plc.
    • Johnson & Johnson Services, Inc.
    • GSK plc.
    • Novartis AG
    • Bristol Myers Squibb
    • Amneal Pharmaceuticals LLC.
    • Sorrento Therapeutics
Product Code: FBI108950

Growth Factors of sciatica treatment Market

The global sciatica treatment market was valued at USD 5.92 billion in 2025 and is projected to grow from USD 6.52 billion in 2026 to USD 14.42 billion by 2034, registering a strong CAGR of 10.44% during the forecast period. North America dominated the market with a 46.1% share in 2025, supported by high awareness of chronic lower back pain, increased prescription volumes, and the presence of leading pharmaceutical companies.

Sciatica, also known as lumbar radicular pain, is characterized by pain radiating from the lower back to the legs due to compression or irritation of the sciatic nerve. The rising incidence of herniated discs, spinal stenosis, and lumbar radiculopathy is driving demand for effective pharmacological and interventional treatment options worldwide.

Market Drivers

A key driver of market growth is the increasing prevalence of sciatica globally, with annual incidence rates ranging from 1.0% to 5.0% and lifetime prevalence between 13% and 40%. The growing use of over-the-counter and prescription drugs, including NSAIDs, corticosteroids, antidepressants, and opioids, has significantly contributed to treatment adoption.

Rising awareness of advanced treatment modalities such as epidural steroid injections and analgesic therapies, along with increased clinical trial activity by market players, is further accelerating market expansion. Additionally, the lack of long-term FDA-approved therapies has encouraged companies to invest in innovative drug development programs.

COVID-19 Impact

The COVID-19 pandemic negatively affected the sciatica treatment market in 2020 due to reduced hospital visits and disruptions in pharmaceutical manufacturing and supply chains. Prescription volumes declined as healthcare systems prioritized COVID-19 care.

However, post-pandemic recovery led to a rebound in patient visits for chronic conditions. By 2021, the relaxation of restrictions resulted in increased demand for sciatica treatments, with pharmaceutical companies witnessing growth in prescription drug sales across hospitals and retail pharmacies.

Market Trends

One of the major trends shaping the market is the rise in awareness programs initiated by healthcare authorities and research institutions. Increased public knowledge about sciatica symptoms, risk factors, and treatment options has improved early diagnosis and treatment uptake.

National and regional initiatives focusing on chronic lower back pain management and the promotion of non-opioid pain therapies are influencing prescribing patterns. The growing availability of minimally invasive procedures and non-opioid medications across healthcare settings is further strengthening market growth.

Restraining Factors

Despite strong growth prospects, the market faces restraints due to side effects and complications associated with long-term sciatica treatments. Chronic use of corticosteroids, opioids, and invasive procedures can lead to significant morbidity, limiting their adoption.

Additionally, sciatica treatment imposes a substantial economic burden due to high direct and indirect healthcare costs. Limited long-term efficacy of existing therapies and concerns regarding complications such as infections and systemic side effects may restrict market growth.

Segmentation Analysis

By Type:

The chronic sciatica segment dominated the market with a 71.47% share in 2026, driven by the high prevalence of long-lasting pain and increased use of epidural injections and opioid therapies. The acute segment is expected to grow steadily due to rising awareness and early treatment adoption.

By Drug Class:

The NSAIDs segment accounted for 44.17% of the market in 2026, supported by widespread availability, affordability, and frequent prescriptions. Corticosteroids are anticipated to witness the fastest growth due to rising demand for epidural steroid injections.

By Distribution Channel:

The retail and online pharmacies segment dominated with an 80.52% share in 2026, driven by high out-of-pocket spending and easy access to pain management medications. Hospital pharmacies are expected to grow steadily due to increasing patient admissions.

Regional Insights

  • North America: Valued at USD 2.73 billion in 2025, driven by high prescription rates and awareness. The U.S. market is projected to reach USD 2.93 billion by 2026.
  • Europe: Moderate growth supported by high disease prevalence and structured pain management guidelines.
  • Asia Pacific: Strong growth potential due to rising lower back pain incidence and government initiatives. By 2026, Japan is projected to reach USD 0.28 billion, China USD 0.24 billion, and India USD 0.17 billion.
  • Latin America & Middle East & Africa: Expected to grow steadily due to expanding access to pain management therapies.

Competitive Landscape

Key players include Pfizer Inc., Abbott, Bayer AG, Johnson & Johnson, Novartis AG, GSK plc., and Sorrento Therapeutics. These companies focus on portfolio expansion, clinical trials, and strategic collaborations to strengthen their market presence.

Conclusion

The global sciatica treatment market is set to witness robust growth from 2025 to 2034, driven by rising disease prevalence, increasing awareness, and growing demand for effective pain management solutions. While concerns regarding side effects and long-term efficacy remain, ongoing clinical research, new drug development, and supportive healthcare initiatives are expected to sustain market momentum. By 2034, the market is projected to reach USD 14.42 billion, reflecting the expanding need for advanced and safer sciatica treatment options worldwide.

Segmentation By Type

  • Acute
  • Chronic

By Drug Class

  • Nonsteroidal Anti-Inflammatory Drugs (NSAIDs)
  • Corticosteroids
  • Antidepressants
  • Others

By Distribution Channel

  • Hospital Pharmacies
  • Retail & Online Pharmacies

By Region

  • North America (By Type, Drug Class, Distribution Channel, and Country)
    • U.S.
    • Canada
  • Europe (By Type, Drug Class, Distribution Channel, and Country/Sub-Region)
    • U.K.
    • Germany
    • France
    • Italy
    • Spain
    • Rest of Europe
  • Asia Pacific (By Type, Drug Class, Distribution Channel, and Country/Sub-Region)
    • China
    • Japan
    • India
    • Australia
    • Southeast Asia
    • Rest of Asia Pacific
  • Latin America (By Type, Drug Class, Distribution Channel, and Country/Sub-Region)
    • Brazil
    • Mexico
    • Rest of Latin America
  • Middle East & Africa (By Type, Drug Class, Distribution Channel, and Country/Sub-Region)
    • GCC
    • South Africa
    • Rest of the Middle East & Africa

Table of Content

1. Introduction

  • 1.1. Research Scope
  • 1.2. Market Segmentation
  • 1.3. Research Methodology
  • 1.4. Definitions and Assumptions

2. Executive Summary

3. Market Dynamics

  • 3.1. Market Drivers
  • 3.2. Market Restraints
  • 3.3. Market Opportunities
  • 3.4. Market Trends

4. Key Insights

  • 4.1. Prevalence of Sciatica, By Key Countries, 2025
  • 4.2. Recent Product Launches, By Key Players
  • 4.3. Key Industry Developments - Mergers, Acquisitions, and Partnerships
  • 4.4. Impact of COVID-19 on the Global Market

5. Global Sciatica Treatment Market Analysis, Insights and Forecast, 2021-2034

  • 5.1. Market Analysis, Insights and Forecast - By Type
    • 5.1.1. Acute
    • 5.1.2. Chronic
  • 5.2. Market Analysis, Insights and Forecast - By Drug Class
    • 5.2.1. Nonsteroidal Anti-Inflammatory Drugs (NSAIDs)
    • 5.2.2. Corticosteroids
    • 5.2.3. Antidepressants
    • 5.2.4. Others
  • 5.3. Market Analysis, Insights and Forecast - By Distribution Channel
    • 5.3.1. Hospital Pharmacies
    • 5.3.2. Retail & Online Pharmacies
  • 5.4. Market Analysis, Insights and Forecast - By Region
    • 5.4.1. North America
    • 5.4.2. Europe
    • 5.4.3. Asia Pacific
    • 5.4.4. Latin America
    • 5.4.5. Middle East and Africa

6. North America Sciatica Treatment Market Analysis, Insights and Forecast, 2021-2034

  • 6.1. Market Analysis, Insights and Forecast - By Type
    • 6.1.1. Acute
    • 6.1.2. Chronic
  • 6.2. Market Analysis, Insights and Forecast - By Drug Class
    • 6.2.1. Nonsteroidal Anti-Inflammatory Drugs (NSAIDs)
    • 6.2.2. Corticosteroids
    • 6.2.3. Antidepressants
    • 6.2.4. Others
  • 6.3. Market Analysis, Insights and Forecast - By Distribution Channel
    • 6.3.1. Hospital Pharmacies
    • 6.3.2. Retail & Online Pharmacies
  • 6.4. Market Analysis, Insights and Forecast - By Country
    • 6.4.1. U.S.
    • 6.4.2. Canada

7. Europe Sciatica Treatment Market Analysis, Insights and Forecast, 2021-2034

  • 7.1. Market Analysis, Insights and Forecast - By Type
    • 7.1.1. Acute
    • 7.1.2. Chronic
  • 7.2. Market Analysis, Insights and Forecast - By Drug Class
    • 7.2.1. Nonsteroidal Anti-Inflammatory Drugs (NSAIDs)
    • 7.2.2. Corticosteroids
    • 7.2.3. Antidepressants
    • 7.2.4. Others
  • 7.3. Market Analysis, Insights and Forecast - By Distribution Channel
    • 7.3.1. Hospital Pharmacies
    • 7.3.2. Retail & Online Pharmacies
  • 7.4. Market Analysis, Insights and Forecast - By Country/Sub-region
    • 7.4.1. U.K.
    • 7.4.2. Germany
    • 7.4.3. France
    • 7.4.4. Spain
    • 7.4.5. Italy
    • 7.4.6. Rest of Europe

8. Asia Pacific Sciatica Treatment Market Analysis, Insights and Forecast, 2021-2034

  • 8.1. Market Analysis, Insights and Forecast - By Type
    • 8.1.1. Acute
    • 8.1.2. Chronic
  • 8.2. Market Analysis, Insights and Forecast - By Drug Class
    • 8.2.1. Nonsteroidal Anti-Inflammatory Drugs (NSAIDs)
    • 8.2.2. Corticosteroids
    • 8.2.3. Antidepressants
    • 8.2.4. Others
  • 8.3. Market Analysis, Insights and Forecast - By Distribution Channel
    • 8.3.1. Hospital Pharmacies
    • 8.3.2. Retail & Online Pharmacies
  • 8.4. Market Analysis, Insights and Forecast - By Country/Sub-region
    • 8.4.1. Japan
    • 8.4.2. China
    • 8.4.3. India
    • 8.4.4. Australia
    • 8.4.5. Southeast Asia
    • 8.4.6. Rest of Asia Pacific

9. Latin America Sciatica Treatment Market Analysis, Insights and Forecast, 2021-2034

  • 9.1. Market Analysis, Insights and Forecast - By Type
    • 9.1.1. Acute
    • 9.1.2. Chronic
  • 9.2. Market Analysis, Insights and Forecast - By Drug Class
    • 9.2.1. Nonsteroidal Anti-Inflammatory Drugs (NSAIDs)
    • 9.2.2. Corticosteroids
    • 9.2.3. Antidepressants
    • 9.2.4. Others
  • 9.3. Market Analysis, Insights and Forecast - By Distribution Channel
    • 9.3.1. Hospital Pharmacies
    • 9.3.2. Retail & Online Pharmacies
  • 9.4. Market Analysis, Insights and Forecast - By Country/Sub-region
    • 9.4.1. Brazil
    • 9.4.2. Mexico
    • 9.4.3. Rest of Latin America

10. Middle East & Africa Sciatica Treatment Market Analysis, Insights and Forecast, 2021-2034

  • 10.1. Market Analysis, Insights and Forecast - By Type
    • 10.1.1. Acute
    • 10.1.2. Chronic
  • 10.2. Market Analysis, Insights and Forecast - By Drug Class
    • 10.2.1. Nonsteroidal Anti-Inflammatory Drugs (NSAIDs)
    • 10.2.2. Corticosteroids
    • 10.2.3. Antidepressants
    • 10.2.4. Others
  • 10.3. Market Analysis, Insights and Forecast - By Distribution Channel
    • 10.3.1. Hospital Pharmacies
    • 10.3.2. Retail & Online Pharmacies
  • 10.4. Market Analysis, Insights and Forecast - By Country/Sub-region
    • 10.4.1. GCC
    • 10.4.2. South Africa
    • 10.4.3. Rest of MEA

11. Competitive Analysis

  • 11.1. Global Market Share Analysis (2025)
  • 11.2. Company Profiles
    • 11.2.1. Pfizer Inc.
      • 11.2.1.1. Overview
      • 11.2.1.2. Products
      • 11.2.1.3. SWOT Analysis
      • 11.2.1.4. Recent Developments
      • 11.2.1.5. Strategies
      • 11.2.1.6. financials (Based on Availability)
    • 11.2.2. Abbott
      • 11.2.2.1. Overview
      • 11.2.2.2. Products
      • 11.2.2.3. SWOT Analysis
      • 11.2.2.4. Recent Developments
      • 11.2.2.5. Strategies
      • 11.2.2.6. financials (Based on Availability)
    • 11.2.3. Bayer AG
      • 11.2.3.1. Overview
      • 11.2.3.2. Products
      • 11.2.3.3. SWOT Analysis
      • 11.2.3.4. Recent Developments
      • 11.2.3.5. Strategies
      • 11.2.3.6. financials (Based on Availability)
    • 11.2.4. Endo International plc.
      • 11.2.4.1. Overview
      • 11.2.4.2. Products
      • 11.2.4.3. SWOT Analysis
      • 11.2.4.4. Recent Developments
      • 11.2.4.5. Strategies
      • 11.2.4.6. financials (Based on Availability)
    • 11.2.5. Johnson & Johnson Services, Inc.
      • 11.2.5.1. Overview
      • 11.2.5.2. Products
      • 11.2.5.3. SWOT Analysis
      • 11.2.5.4. Recent Developments
      • 11.2.5.5. Strategies
      • 11.2.5.6. financials (Based on Availability)
    • 11.2.6. GSK plc.
      • 11.2.6.1. Overview
      • 11.2.6.2. Products
      • 11.2.6.3. SWOT Analysis
      • 11.2.6.4. Recent Developments
      • 11.2.6.5. Strategies
      • 11.2.6.6. financials (Based on Availability)
    • 11.2.7. Novartis AG
      • 11.2.7.1. Overview
      • 11.2.7.2. Products
      • 11.2.7.3. SWOT Analysis
      • 11.2.7.4. Recent Developments
      • 11.2.7.5. Strategies
      • 11.2.7.6. financials (Based on Availability)
    • 11.2.8. Bristol Myers Squibb
      • 11.2.8.1. Overview
      • 11.2.8.2. Products
      • 11.2.8.3. SWOT Analysis
      • 11.2.8.4. Recent Developments
      • 11.2.8.5. Strategies
      • 11.2.8.6. financials (Based on Availability)
    • 11.2.9. Amneal Pharmaceuticals LLC.
      • 11.2.9.1. Overview
      • 11.2.9.2. Products
      • 11.2.9.3. SWOT Analysis
      • 11.2.9.4. Recent Developments
      • 11.2.9.5. Strategies
      • 11.2.9.6. financials (Based on Availability)
    • 11.2.10. Sorrento Therapeutics
      • 11.2.10.1. Overview
      • 11.2.10.2. Products
      • 11.2.10.3. SWOT Analysis
      • 11.2.10.4. Recent Developments
      • 11.2.10.5. Strategies
      • 11.2.10.6. financials (Based on Availability)

List of Tables

  • Table 1: Global Sciatica Treatment Market Revenue (USD billion) Forecast, by Type, 2021-2034
  • Table 2: Global Sciatica Treatment Market Revenue (USD billion) Forecast, by By Drug Class, 2021-2034
  • Table 3: Global Sciatica Treatment Market Revenue (USD billion) Forecast, by Distribution Channel, 2021-2034
  • Table 4: Global Sciatica Treatment Market Revenue (USD billion) Forecast, by Region, 2021-2034
  • Table 5: North America Sciatica Treatment Market Revenue (USD billion) Forecast, by Type, 2021-2034
  • Table 6: North America Sciatica Treatment Market Revenue (USD billion) Forecast, by Drug Class, 2021-2034
  • Table 7: North America Sciatica Treatment Market Revenue (USD billion) Forecast, by Distribution Channel, 2021-2034
  • Table 8: North America Sciatica Treatment Market Revenue (USD billion) Forecast, By Country, 2021-2034
  • Table 9: Europe Sciatica Treatment Market Revenue (USD billion) Forecast, by Type, 2021-2034
  • Table 10: Europe Sciatica Treatment Market Revenue (USD billion) Forecast, by Drug Class, 2021-2034
  • Table 11: Europe Sciatica Treatment Market Revenue (USD billion) Forecast, by Distribution Channel, 2021-2034
  • Table 12: Europe Sciatica Treatment Market Revenue (USD billion) Forecast, By Country/ Sub-region, 2021-2034
  • Table 13: Asia Pacific Sciatica Treatment Market Revenue (USD billion) Forecast, by Type, 2021-2034
  • Table 14: Asia Pacific Sciatica Treatment Market Revenue (USD billion) Forecast, by Drug Class, 2021-2034
  • Table 15: Asia Pacific Sciatica Treatment Market Revenue (USD billion) Forecast, by Distribution Channel, 2021-2034
  • Table 16: Asia Pacific Sciatica Treatment Market Revenue (USD billion) Forecast, By Country/ Sub-region, 2021-2034
  • Table 17: Latin America Sciatica Treatment Market Revenue (USD billion) Forecast, by Type, 2021-2034
  • Table 18: Latin America Sciatica Treatment Market Revenue (USD billion) Forecast, by Drug Class, 2021-2034
  • Table 19: Latin America Sciatica Treatment Market Revenue (USD billion) Forecast, by Distribution Channel, 2021-2034
  • Table 20: Latin America Sciatica Treatment Market Revenue (USD billion) Forecast, By Country/ Sub-region, 2021-2034
  • Table 21: Middle East & Africa Sciatica Treatment Market Revenue (USD billion) Forecast, by Type, 2021-2034
  • Table 22: Middle East & Africa Sciatica Treatment Market Revenue (USD billion) Forecast, by Drug Class, 2021-2034
  • Table 23: Middle East & Africa Sciatica Treatment Market Revenue (USD billion) Forecast, by Distribution Channel, 2021-2034
  • Table 24: Middle East & Africa Sciatica Treatment Market Revenue (USD billion) Forecast, By Country/ Sub-region, 2021-2034

List of Figures

  • Figure 1: Global Sciatica Treatment Market Revenue Breakdown (USD billion, %) by Region, 2025 & 2034
  • Figure 2: Global Sciatica Treatment Market Value Share (%), by Type, 2025 & 2034
  • Figure 3: Global Sciatica Treatment Market Value Share (%), by Drug Class, 2025 & 2034
  • Figure 4: Global Sciatica Treatment Market Value Share (%), by Distribution Channel, 2025 & 2034
  • Figure 5: Global Sciatica Treatment Market Value (USD billion), by Region, 2025 & 2034
  • Figure 6: North America Sciatica Treatment Market Value (USD billion), by Type, 2025 & 2034
  • Figure 7: North America Sciatica Treatment Market Value Share (%), by Type, 2025
  • Figure 8: North America Sciatica Treatment Market Value (USD billion), by Drug Class, 2025 & 2034
  • Figure 9: North America Sciatica Treatment Market Value Share (%), by Drug Class, 2025
  • Figure 10: North America Sciatica Treatment Market Value (USD billion), by Distribution Channel, 2025 & 2034
  • Figure 11: North America Sciatica Treatment Market Value Share (%), by Distribution Channel, 2025
  • Figure 12: North America Sciatica Treatment Market Value (USD billion), By Country, 2025 & 2034
  • Figure 13: North America Sciatica Treatment Market Value Share (%), By Country, 2025
  • Figure 14: Europe Sciatica Treatment Market Value (USD billion), by Type, 2025 & 2034
  • Figure 15: Europe Sciatica Treatment Market Value Share (%), by Type, 2025
  • Figure 16: Europe Sciatica Treatment Market Value (USD billion), by Drug Class, 2025 & 2034
  • Figure 17: Europe Sciatica Treatment Market Value Share (%), by Drug Class, 2025
  • Figure 18: Europe Sciatica Treatment Market Value (USD billion), by Distribution Channel, 2025 & 2034
  • Figure 19: Europe Sciatica Treatment Market Value Share (%), by Distribution Channel, 2025
  • Figure 20: Europe Sciatica Treatment Market Value (USD billion), By Country/ Sub-region, 2025 & 2034
  • Figure 21: Europe Sciatica Treatment Market Value Share (%), By Country/ Sub-region, 2025
  • Figure 22: Asia Pacific Sciatica Treatment Market Value (USD billion), by Type, 2025 & 2034
  • Figure 23: Asia Pacific Sciatica Treatment Market Value Share (%), by Type, 2025
  • Figure 24: Asia Pacific Sciatica Treatment Market Value (USD billion), by Drug Class, 2025 & 2034
  • Figure 25: Asia Pacific Sciatica Treatment Market Value Share (%), by Drug Class, 2025
  • Figure 26: Asia Pacific Sciatica Treatment Market Value (USD billion), by Distribution Channel, 2025 & 2034
  • Figure 27: Asia Pacific Sciatica Treatment Market Value Share (%), by Distribution Channel, 2025
  • Figure 28: Asia Pacific Sciatica Treatment Market Value (USD billion), By Country/ Sub-region, 2025 & 2034
  • Figure 29: Asia Pacific Sciatica Treatment Market Value Share (%), By Country/ Sub-region, 2025
  • Figure 30: Latin America Sciatica Treatment Market Value (USD billion), by Type, 2025 & 2034
  • Figure 31: Latin America Sciatica Treatment Market Value Share (%), by Type, 2025
  • Figure 32: Latin America Sciatica Treatment Market Value (USD billion), by Drug Class, 2025 & 2034
  • Figure 33: Latin America Sciatica Treatment Market Value Share (%), by Drug Class, 2025
  • Figure 34: Latin America Sciatica Treatment Market Value (USD billion), by Distribution Channel, 2025 & 2034
  • Figure 35: Latin America Sciatica Treatment Market Value Share (%), by Distribution Channel, 2025
  • Figure 36: Latin America Sciatica Treatment Market Value (USD billion), By Country/ Sub-region, 2025 & 2034
  • Figure 37: Latin America Sciatica Treatment Market Value Share (%), By Country/ Sub-region, 2025
  • Figure 38: Middle East & Africa Sciatica Treatment Market Value (USD billion), by Type, 2025 & 2034
  • Figure 39: Middle East & Africa Sciatica Treatment Market Value Share (%), by Type, 2025
  • Figure 40: Middle East & Africa Sciatica Treatment Market Value (USD billion), by Drug Class, 2025 & 2034
  • Figure 41: Middle East & Africa Sciatica Treatment Market Value Share (%), by Drug Class, 2025
  • Figure 42: Middle East & Africa Sciatica Treatment Market Value (USD billion), by Distribution Channel, 2025 & 2034
  • Figure 43: Middle East & Africa Sciatica Treatment Market Value Share (%), by Distribution Channel, 2025
  • Figure 44: Middle East & Africa Sciatica Treatment Market Value (USD billion), By Country/ Sub-region, 2025 & 2034
  • Figure 45: Middle East & Africa Sciatica Treatment Market Value Share (%), By Country/ Sub-region, 2025
  • Figure 46: Global Sciatica Treatment Market Share (%), By Company, 2025